Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADUS Addus HomeCare	$111.75 +0.7%	$112.46	$88.96 ▼ $136.72	$2.06B	0.81	165,824 shs	100,284 shs
ARDT Ardent Health	$14.51 +2.4%	$14.00	$11.31 ▼ $20.72	$2.08B	N/A	380,867 shs	438,315 shs
CSTL Castle Biosciences	$19.50 -0.8%	$18.01	$15.45 ▼ $35.84	$562.97M	1.1	419,768 shs	231,094 shs
VCYT Veracyte	$26.65 -1.6%	$27.72	$19.73 ▼ $47.32	$2.09B	2.07	917,605 shs	663,848 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADUS Addus HomeCare	+0.75%	+1.02%	-0.93%	+12.61%	-7.57%
ARDT Ardent Health	+2.26%	+8.77%	+10.43%	+17.35%	+1,450,999,900.00%
CSTL Castle Biosciences	-0.81%	+0.21%	+4.00%	-7.36%	+5.12%
VCYT Veracyte	-1.59%	+1.18%	+0.79%	-16.09%	+17.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADUS Addus HomeCare	4.979 of 5 stars	3.6	4.0	5.0	3.7	2.5	3.1
ARDT Ardent Health	3.3441 of 5 stars	3.5	0.0	0.0	2.2	0.0	3.1
CSTL Castle Biosciences	2.2982 of 5 stars	3.5	2.0	0.0	2.5	2.5	0.0
VCYT Veracyte	3.5871 of 5 stars	3.4	1.0	4.3	2.7	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADUS Addus HomeCare	3.25	Buy	$142.57	27.58% Upside
ARDT Ardent Health	3.00	Buy	$20.67	42.43% Upside
CSTL Castle Biosciences	3.00	Buy	$37.00	89.74% Upside
VCYT Veracyte	2.70	Moderate Buy	$40.90	53.47% Upside

Current Analyst Ratings Breakdown

Latest CSTL, VCYT, ARDT, and ADUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	ADUS Addus HomeCare	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$150.00
6/10/2025	ADUS Addus HomeCare	Macquarie Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$133.00
5/21/2025	CSTL Castle Biosciences	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$44.00 ➝ $40.00
5/20/2025	ARDT Ardent Health	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$21.00 ➝ $21.00
5/15/2025	ARDT Ardent Health	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$21.00 ➝ $21.00
5/9/2025	ARDT Ardent Health	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$16.00 ➝ $18.00
5/8/2025	ADUS Addus HomeCare	Macquarie Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$129.00 ➝ $133.00
5/8/2025	VCYT Veracyte	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$49.00 ➝ $42.00
5/8/2025	VCYT Veracyte	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$51.00 ➝ $41.00
5/6/2025	CSTL Castle Biosciences	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $35.00
5/6/2025	CSTL Castle Biosciences	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$42.00 ➝ $37.00

(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADUS Addus HomeCare	$1.15B	1.78	$5.43 per share	20.58	$53.52 per share	2.09
ARDT Ardent Health	$5.97B	0.35	$2.60 per share	5.59	$10.66 per share	1.36
CSTL Castle Biosciences	$332.07M	1.70	$0.98 per share	19.98	$16.28 per share	1.20
VCYT Veracyte	$445.76M	4.68	$1.02 per share	26.12	$15.17 per share	1.76

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADUS Addus HomeCare	$73.60M	$4.43	25.23	20.85	1.57	6.52%	9.23%	6.96%	8/4/2025 (Estimated)
ARDT Ardent Health	$210.34M	$1.63	8.90	7.40	1.28	3.73%	16.07%	4.69%	8/13/2025 (Estimated)
CSTL Castle Biosciences	$18.25M	-$0.19	N/A	N/A	N/A	-1.46%	3.41%	2.95%	8/4/2025 (Estimated)
VCYT Veracyte	$24.14M	$0.41	65.00	37.01	N/A	7.13%	6.14%	5.60%	8/5/2025 (Estimated)

Latest CSTL, VCYT, ARDT, and ADUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	VCYT Veracyte	$0.31	N/A	N/A	N/A	$120.90 million	N/A
8/4/2025	Q2 2025	ADUS Addus HomeCare	$1.45	N/A	N/A	N/A	$345.71 million	N/A
8/4/2025	Q2 2025	CSTL Castle Biosciences	-$0.44	N/A	N/A	N/A	$71.53 million	N/A
5/6/2025	Q1 2025	ARDT Ardent Health	$0.21	$0.29	+$0.08	$0.29	$1.50 billion	$1.50 billion
5/5/2025	Q1 2025	ADUS Addus HomeCare	$1.33	$1.42	+$0.09	$1.16	$341.66 million	$337.71 million
5/5/2025	Q1 2025	CSTL Castle Biosciences	-$0.08	-$0.20	-$0.12	-$0.90	$80.40 million	$87.99 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADUS Addus HomeCare	N/A	N/A	N/A	N/A	N/A
ARDT Ardent Health	N/A	N/A	N/A	N/A	N/A
CSTL Castle Biosciences	N/A	N/A	N/A	N/A	N/A
VCYT Veracyte	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADUS Addus HomeCare	0.20	1.74	1.74
ARDT Ardent Health	0.70	2.12	1.98
CSTL Castle Biosciences	0.02	9.37	9.19
VCYT Veracyte	N/A	5.10	4.78

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADUS Addus HomeCare	95.35%
ARDT Ardent Health	N/A
CSTL Castle Biosciences	92.60%
VCYT Veracyte	N/A

Insider Ownership

Company	Insider Ownership
ADUS Addus HomeCare	4.60%
ARDT Ardent Health	1.70%
CSTL Castle Biosciences	7.20%
VCYT Veracyte	1.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADUS Addus HomeCare	49,703	18.40 million	17.55 million	Optionable
ARDT Ardent Health	24,900	143.04 million	140.61 million	Optionable
CSTL Castle Biosciences	540	28.87 million	26.79 million	Optionable
VCYT Veracyte	790	78.32 million	77.22 million	Optionable

CSTL, VCYT, ARDT, and ADUS Headlines

Recent News About These Companies

Rice Hall James & Associates LLC Acquires 19,843 Shares of Veracyte, Inc. (NASDAQ:VCYT)

3 hours ago | marketbeat.com

Veracyte, Inc. (NASDAQ:VCYT) Shares Sold by Teacher Retirement System of Texas

July 14 at 3:46 AM | marketbeat.com

Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025 - Morningstar

July 10, 2025 | morningstar.comM

Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025

July 9, 2025 | tmcnet.com

Wealth Enhancement Advisory Services LLC Grows Holdings in Veracyte, Inc. (NASDAQ:VCYT)

July 6, 2025 | marketbeat.com

Veracyte, Inc. (VCYT) - Yahoo Finance

July 3, 2025 | finance.yahoo.com

Veracyte, Inc. (NASDAQ:VCYT) Shares Sold by Sumitomo Mitsui Trust Group Inc.

July 1, 2025 | marketbeat.com

Wall Street Zen Downgrades Veracyte (NASDAQ:VCYT) to Hold

June 28, 2025 | marketbeat.com

AMI Asset Management Corp Has $1.44 Million Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT)

June 26, 2025 | marketbeat.com

Veracyte, Inc. (NASDAQ:VCYT) Receives Average Rating of "Moderate Buy" from Analysts

June 23, 2025 | marketbeat.com

Veracyte (NASDAQ:VCYT) shareholders have earned a 19% return over the last year

June 20, 2025 | finance.yahoo.com

GAMMA Investing LLC Purchases 18,840 Shares of Veracyte, Inc. (NASDAQ:VCYT)

June 19, 2025 | marketbeat.com

Cathie Wood’s ARK buys BWX stock, sells Adaptive Biotech

June 18, 2025 | investing.com

Exchange Traded Concepts LLC Increases Stake in Veracyte, Inc. (NASDAQ:VCYT)

June 17, 2025 | marketbeat.com

Veracyte (VCYT) Fell Despite Reporting Revenue Growth and Improved Profitability

June 9, 2025 | msn.com

Cathie Wood's Ark Invest Loads Up On Veracyte, Offloads 3D Systems

June 7, 2025 | benzinga.com

Insider Selling: John Leite Sells Shares of Veracyte Inc (VCYT)

June 6, 2025 | gurufocus.com

Veracyte (VCYT) Down 13.6% Since Last Earnings Report: Can It Rebound?

June 6, 2025 | msn.com

Cathie Wood’s ARK sells Palantir and Roblox, buys Veracyte and Guardant

June 4, 2025 | investing.com

Veracyte (VCYT) Shares Pulled Back Despite Beating Expectations

June 3, 2025 | msn.com

Veracyte, Inc. (VCYT) Presents Breakthrough Genomic Data to Predict Cancer Therapy Response at ASCO

May 28, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CSTL, VCYT, ARDT, and ADUS Company Descriptions

Addus HomeCare NASDAQ:ADUS

$111.75 +0.83 (+0.75%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$111.62 -0.13 (-0.11%)

As of 07/14/2025 04:07 PM Eastern

Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living. This segment offers services that include assistance with bathing, grooming, oral care, feeding and dressing, medication reminders, meal planning and preparation, housekeeping, and transportation services. The Hospice segment provides palliative nursing care, social work, spiritual counseling, homemaker, and bereavement counseling services for people who are terminally ill, as well as related services for their families. The Home Health segment offers skilled nursing and physical, occupational, and speech therapy for the individuals who requires assistance during an illness or after hospitalization. The company's payor clients include federal, state, and local governmental agencies; managed care organizations; commercial insurers; and private individuals. Addus HomeCare Corporation was founded in 1979 and is headquartered in Frisco, Texas.

Ardent Health NYSE:ARDT

$14.51 +0.34 (+2.40%)

Closing price 07/14/2025 03:59 PM Eastern

Extended Trading

$14.50 -0.01 (-0.10%)

As of 07/14/2025 07:06 PM Eastern

Ardent Health Partners, Inc. owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee. Ardent Health Partners, Inc. is a subsidiary of EGI-AM Investments, L.L.C.

Castle Biosciences NASDAQ:CSTL

$19.50 -0.16 (-0.81%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$20.16 +0.66 (+3.38%)

As of 07:27 AM Eastern

Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

Veracyte NASDAQ:VCYT

$26.65 -0.43 (-1.59%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$27.43 +0.78 (+2.92%)

As of 08:33 AM Eastern

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time